Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kang-ai Injection
- Development stage
- Preclinical
- Lead developer
- Jilin Changbaishan Pharmaceutical Group
- Administration
- Intravenous
01
Overview
Kang-ai Injection (KAI) is a Traditional Chinese Medicine (TCM) injection derived from a combination of extracts from Astragalus (milkvetch root), Ginseng, and Sophora flavescens (Kushen). It is authorized and widely used in China as an adjuvant therapy for various cancers, including hepatocellular carcinoma, non-small cell lung cancer, and colorectal cancer. KAI is known for its beneficial effects such as enhancing immune function, reducing side effects of chemotherapy, and improving chemotherapy sensitivity. Its proposed mechanisms of action involve inhibiting tumor cell proliferation, invasion, and metastasis, inducing tumor cell apoptosis, and modulating specific signaling pathways like PI3K-AKT and IL-6/STAT3.
- Other names
- Kang AiKAIKA
02
Targets
CCND1 (Cyclin D1)RB1 (Retinoblastoma-associated Protein)Tumor necrosis factor receptor 2 (TNFR2)/Phosphatidylinositol 3-kinase (PI3K)/Protein kinase B (AKT)/Nuclear factor kappa B (NF-κB) axisCDKN1A (Cyclin-dependent kinase inhibitor 1A)CD3 (T-cell surface glycoprotein CD3 complex)CD4 (T lymphocyte surface antigen)IL-6 (Interleukin 6)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)AKT (RAC-alpha serine/threonine-protein kinase)STAT3 (Signal Transducer and Activator of Transcription 3)
Beyond the preview
Go deeper on Kang-ai Injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kang-ai Injection.